Loading
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
Latest quote
¥792
+¥96.00 · +13.79%
Regular session · JST · Market data may be delayed.
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
Day range
Current ¥792
52-week range
Current ¥792
Regular session · JST · Market data may be delayed.
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
Day range
Current ¥792
52-week range
Current ¥792
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
